Cellectis plans to use funds for UCART development and commercialization

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said it would use $100 million from a recent financing to establish a manufacturing facility for its UCART candidates. Cellectis also intends to use about $20 million to advance an additional UCART product and about $30 million to develop gene-editing therapies outside oncology.

The company out-lined plans in an SEC filing that accompanied its $175 million follow-on from earlier this month (see BioCentury, April 6)...